FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, particularly to an antibody which specifically binds to PD-1. Also disclosed is a composition comprising said antibody, a nucleic acid encoding said antibody, a vector and a host cell containing said nucleic acid. Disclosed are methods of treating cancer and infectious disease, diagnosing, selecting, detecting, amplifying using said antibody, a method for producing said antibody, a method of reproducing a population of T-cells and using said antibody for preparing a drug for detecting PD-1.
EFFECT: invention provides effective treatment of diseases associated with PD-1.
21 cl, 24 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| BINDING MOLECULES SPECIFIC FOR CD73, AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2730665C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| ANTIBODIES AGAINST PROGRAMMED CELL DEATH LIGAND 1 AND THEIR USE | 2020 |
|
RU2786235C1 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| ANTIBODY AGAINST TNFR2 AND ITS APPLICATION | 2020 |
|
RU2793165C1 |
